drugset / Trial / NCT00237380

Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis

NCT00237380

Phase 2 Completed 24 enrolled PTC Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.

Timeline

Start
2005-11-30
Primary completion
2006-05-31
Completion
2006-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ataluren Small molecule 16 mg/kg Oral
Subject Ataluren Small molecule 40 mg/kg Oral

Indications